YCYueh-Yi Chiang

Yueh-Yi Chiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yueh-Yi Chiang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Susan Dosreis

    Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore

    2 shared publications
  • Alejandro Amill-Rosario

    Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore

    1 shared publication
  • Charmaine Rochester-Eyeguokan

    Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore

    1 shared publication
  • Eberechukwu Onukwugha

    Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore

    1 shared publication
  • Phuong Tran

    Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore

    1 shared publication

Latest Publications

  • Comorbid depression and anxiety and their association with health care resource utilization among individuals with type 1 diabetes in the United States

    by Yueh-Yi Chiang, Susan Dosreis, Charmaine Rochester-Eyeguokan, Eberechukwu Onukwugha

    Type 1 diabetes mellitus (T1DM) is a prevalent chronic endocrine disorder and accounts for 5%-10% of all diabetes cases worldwide. T1DM can have a substantial impact on health care utilization. Although it is well known that individuals with diabetes are at a greater risk of mental health disorders, specific evidence addressing the health care burden of comorbid depression/anxiety in people affected by T1DM is lacking. To assess health care resource utilization (HCRU) among adults with T1DM and comorbid depression or anxiety. We identified individuals aged 18 to 64 with a T1DM diagnosis from January 1, 2017, to December 31, 2021, using a 25% random sample of the IQVIA PharMetrics Plus for Academics database. The index date was the date of the first medical claim with a T1DM diagnosis. Eligibility required continuous medical and prescription coverage for 12 months before (baseline) and after (follow-up) the index date. Comorbid depression/anxiety and baseline characteristics were assessed during the baseline period. The following 2 mutually exclusive groups were created: individuals with T1DM and comorbid depression/anxiety, and those with only T1DM. To balance baseline demographic and clinical characteristics between the groups, we implemented 1:1 propensity-score matching. We assessed all-cause, diabetes-related, and major adverse cardiovascular event−related HCRU during the follow-up period. Logistic (binary) and negative binomial (count) regression models examined the association between comorbid depression/anxiety and HCRU across types of health care settings. Out of 6,491 eligible individuals with T1DM, 1,168 (18%) had either depression or anxiety. In the matched cohort of 2,314 individuals, those with T1DM and comorbid depression/anxiety had significantly higher odds of all-cause emergency department visits (odds ratio = 1.67; 95% CI = 1.39-2.00) and higher rates of physician office visits (incidence rate ratio = 1.37; 95% CI = 1.27-1.47) and other outpatient encounters (incidence rate ratio = 1.23; 95% CI = 1.13-1.34) than those with only T1DM. Findings were similar for diabetes-related and major adverse cardiovascular event−related HCRU. Comorbid depression/anxiety among individuals with T1DM results in significantly higher HCRU than T1DM alone. The findings underscore the importance of effective management of comorbid depression/anxiety in the T1DM population.


  • Open Access

    Psychotropic Polypharmacy Among Youths Enrolled in Medicaid

    by Yueh-Yi Chiang, Alejandro Amill-Rosario, Phuong Tran, Susan Dosreis

    Concomitant use of medications for attention-deficit/hyperactivity disorder (ADHD), antipsychotics, mood-stabilizing anticonvulsants, and antidepressants is referred to as psychotropic polypharmacy.1 Over the past 2 decades, psychotropic polypharmacy in youths increased, raising safety concerns.2-4 Our goal was to examine trends from 2015 to 2020 in psychotropic polypharmacy among youths aged 17 years or younger who were enrolled in Medicaid to identify temporal changes and characteristics associated with psychotropic polypharmacy.